%0 Journal Article %A Taufiqur Rahman Bhuiyan %A Juan Dent Hulse %A Sonia T. Hegde %A Marjahan Akhtar %A Md. Taufiqul Islam %A Zahid Hasan Khan %A Ishtiakul Islam Khan %A Md Mamunur Rashid %A Rumana Rashid %A Emily S. Gurley %A Tahmina Shirin %A Ashraful Islam Khan %A Andrew S. Azman %A Firdausi Qadri %T SARS-CoV-2 seroprevalence in Chattogram, Bangladesh before a National Lockdown, March-April 2021 %D 2021 %R 10.1101/2021.07.16.21260611 %J medRxiv %P 2021.07.16.21260611 %X The absence of population-based seroprevalence estimates in Bangladesh have impeded efforts to understand the relatively low reported mortality and incidence rates of SARS-CoV-2 in this country. We report findings of a representative serosurvey of the Sitakunda subdistrict in the Chattogram division of Bangladesh before a nationwide lockdown in April 2021. After adjusting for age, sex, household clustering and test performance using a Bayesian modeling approach, we estimate the seroprevalence of SARS-CoV-2 to have been 63.1% (56.2–60.8%) in Sitakunda during this period. These results illustrate that going into the national lockdown in April 2021, the majority of this population had already been infected despite a relatively low incidence of medically attended COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Bill and Melinda Gates Foundation [grant number INV-021879]. The authors would like to thank the Ministry of Health and Family Welfare (MOHFW) of Bangladesh. The authors would also like to express their sincere thanks to the staff members of icddr,b for their dedicated work in the field and laboratory during this pandemic situation. icddr,b is thankful and supported by the Governments of Bangladesh, Canada, Sweden, and the UK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was given by ethical review committees from both Johns Hopkins University and International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting these estimates are publicly available in the sitakunda-sarscov2-round1 repository in Github. https://github.com/HopkinsIDD/sitakunda-sarscov2-round1 %U https://www.medrxiv.org/content/medrxiv/early/2021/07/20/2021.07.16.21260611.full.pdf